Bo Jin

1.5k total citations
71 papers, 972 citations indexed

About

Bo Jin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Bo Jin has authored 71 papers receiving a total of 972 indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Pulmonary and Respiratory Medicine, 40 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Bo Jin's work include Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (18 papers) and Lung Cancer Diagnosis and Treatment (16 papers). Bo Jin is often cited by papers focused on Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (18 papers) and Lung Cancer Diagnosis and Treatment (16 papers). Bo Jin collaborates with scholars based in China, Australia and United States. Bo Jin's co-authors include Baohui Han, Jianlin Xu, Yanwei Zhang, Yuqing Lou, Xiujuan Qu, David J. Handelsman, Xueyan Zhang, Mingfang Zhao, Yuee Teng and Yu Dong and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Bo Jin

66 papers receiving 965 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bo Jin China	17	703	527	202	147	134	71	972
Alessia Mennitto Italy	19	479 0.7×	549 1.0×	271 1.3×	225 1.5×	212 1.6×	59	1.0k
Teodoro Sava Italy	18	554 0.8×	502 1.0×	292 1.4×	231 1.6×	282 2.1×	69	1.1k
A. Kooistra Netherlands	12	576 0.8×	403 0.8×	326 1.6×	198 1.3×	110 0.8×	19	928
M. Neil Reaume Canada	18	642 0.9×	461 0.9×	302 1.5×	218 1.5×	234 1.7×	66	1.1k
Anthony A. Meluch United States	17	584 0.8×	384 0.7×	232 1.1×	134 0.9×	485 3.6×	44	1.1k
Satoshi Fukasawa Japan	17	709 1.0×	339 0.6×	183 0.9×	122 0.8×	170 1.3×	61	929
Alejo Rodríguez‐Vida Spain	18	686 1.0×	484 0.9×	359 1.8×	263 1.8×	302 2.3×	95	1.1k
Mimma Rizzo Italy	17	696 1.0×	428 0.8×	484 2.4×	333 2.3×	97 0.7×	78	1.1k
Masayuki Hagiwara Japan	17	265 0.4×	299 0.6×	311 1.5×	126 0.9×	280 2.1×	58	819
Jeff White United Kingdom	16	279 0.4×	363 0.7×	332 1.6×	77 0.5×	209 1.6×	53	898

Countries citing papers authored by Bo Jin

Since Specialization

Citations

This map shows the geographic impact of Bo Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Jin more than expected).

Fields of papers citing papers by Bo Jin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bo Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Jin. The network helps show where Bo Jin may publish in the future.

Co-authorship network of co-authors of Bo Jin

This figure shows the co-authorship network connecting the top 25 collaborators of Bo Jin. A scholar is included among the top collaborators of Bo Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bo Jin. Bo Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Yang, Bo Jin, Tianyang Zhang, et al.. (2025). LDHA facilitates immune escape in bladder cancer through H4K5 lactylation-dependent upregulation of PD-L1. Biochemical Pharmacology. 243(Pt 2). 117553–117553.

Zhou, Xuan, Bo Jin, Bo Wang, et al.. (2025). Efficacy and safety of chimeric antigen receptor T cell therapy combined with zanubrutinib in the treatment of relapsed/refractory diffuse large B-cell lymphoma. Chinese Medical Journal. 138(6). 748–750. 1 indexed citations

Pokhrel, Gaurab, Bo Jin, Yonghao Zhan, et al.. (2025). Initial experience with the novel modular robotic system Carina in urology: a prospective study on safety feasibility and surgical settings. Scientific Reports. 15(1). 12686–12686. 1 indexed citations

Yang, Xue, Yutao Liu, Jinliang Wang, et al.. (2025). Comparison of the effectiveness of alectinib versus crizotinib followed by alectinib in patients with ALK-positive advanced non-small-cell lung cancer in real-world setting and in the ALEX study. Translational Lung Cancer Research. 14(4). 1158–1167.

Wang, Jie, Nong Yang, Dongqing Lv, et al.. (2025). Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET -amplification ( MET amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.. Journal of Clinical Oncology. 43(17_suppl). 3 indexed citations

Jin, Bo, Yunpeng Liu, Bowen Yang, et al.. (2023). Construction of the prognostic model for small‐cell lung cancer based on inflammatory markers: A real‐world study of 612 cases with eastern cooperative oncology group performance score 0–1. Cancer Medicine. 12(8). 9527–9540. 7 indexed citations

Liu, Jing, Bo Jin, Hang Su, Xiujuan Qu, & Yunpeng Liu. (2019). Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report. BMC Cancer. 19(1). 702–702. 33 indexed citations

Yu, Ping, Mingyi Zhou, Jinglei Qu, et al.. (2018). The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients. BMC Cancer. 18(1). 1076–1076. 13 indexed citations

Jin, Bo, Simeng Zhang, Ping Yu, et al.. (2018). Breast cancer and synchronous multiple primary lung adenocarcinomas with heterogeneous mutations: a case report. BMC Cancer. 18(1). 1138–1138. 7 indexed citations

10.

Wang, Huimin, Yanwei Zhang, Jiajun Teng, et al.. (2017). P1.03-062 Lung Cancer Screening with Low-Dose CT in China: Study Design and Baseline Results from the First Round Screening Arm. Journal of Thoracic Oncology. 12(1). S581–S582. 2 indexed citations

11.

Qian, Fangfei, Wenjia Yang, Rui Wang, et al.. (2017). Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery. 155(3). 1227–1235.e2. 68 indexed citations

12.

Zhang, Yanwei, et al.. (2016). Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations. Journal of Cancer Research and Therapeutics. 12(1). 254–254. 7 indexed citations

13.

Xu, Jianlin, Xueyan Zhang, Bo Jin, et al.. (2016). The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China. OncoTargets and Therapy. Volume 9. 6479–6484. 3 indexed citations

14.

Wang, Jin, Jinglei Qu, Zhi Li, et al.. (2016). A Prognostic Model in Metastatic or Recurrent Gastric Cancer Patients with Good Performance Status Who Received First-Line Chemotherapy. Translational Oncology. 9(3). 256–261. 17 indexed citations

15.

Xu, Jianlin, Yanwei Zhang, Bo Jin, et al.. (2016). Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. Journal of Cancer Research and Clinical Oncology. 142(6). 1325–1330. 17 indexed citations

16.

Ren, Weihong, Jun Qi, Bo Jin, et al.. (2016). EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer. Oncology Letters. 11(4). 2371–2378. 15 indexed citations

17.

Shao, Minhua, Bo Jin, Yanjie Niu, et al.. (2014). Association of POLK Polymorphisms with Platinum-Based Chemotherapy Response and Severe Toxicity in Non-small Cell Lung Cancer Patients. Cell Biochemistry and Biophysics. 70(2). 1227–1237. 19 indexed citations

18.

Zhang, Yanwei, Bo Jin, Minhua Shao, et al.. (2014). Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma. Tumor Biology. 35(5). 4921–4928. 20 indexed citations

19.

Teng, Yuee, Bo Jin, Mingfang Zhao, et al.. (2010). Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer. BMC Cancer. 10(1). 681–681. 21 indexed citations

20.

Jin, Bo, Geoffrey W. McCaughan, & David J. Handelsman. (1999). Effects of Liver Disease and Transplantation on the Human Prostate. Journal of Andrology. 20(4). 559–565. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact